Low debt and equity capacity
Total liabilities were KRW 5 billion at year-end 2025 against KRW 42.6 billion of total equity. With the debt burden relative to equity reduced, the company has room to fund cosmetics capacity and overseas certification.
PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩140 per share · Prices as of the 2026-11-18 close
Wonbiogen has built a cosmetics second leg on top of its wound-dressing ODM core and grew revenue and operating profit from 2022 onward. The next checkpoints are whether cosmetics growth holds and how the loss-making subsidiary J&COS develops.
Revenue rose from KRW 26.7 billion in 2022 to KRW 35.2 billion in 2025, increasing for three consecutive years from 2023 to 2025.
The operating margin peaked at 24.1% in 2023, dipped to 21.0% in 2024, and recovered to 22.5% in 2025.
On a press-tallied basis, cosmetics rose from 2.64% of revenue in 2021 to 29.59% in 2025.
Q3 2026 revenue was KRW 10.8 billion, up 17.0% year on year, and operating profit of KRW 2.93 billion has risen for three consecutive quarters.
The subsidiary J&COS continued to post operating losses and booked impairment charges in 2025, leaving it as a source of volatility in consolidated results.
Wonbiogen was founded in 2006 and listed on KOSDAQ in 2021 through a reverse merger with a special purpose acquisition company. Its core is wound care: polyurethane foam dressings and hydrocolloid dressings supplied on an ODM basis.
The second pillar is cosmetics, sold under the in-house MEDISORB brand as medical-device cosmetics, including sheet masks, serums and moisturizing creams. Cosmetics revenue grew more than tenfold between 2021 and 2023, according to company data cited in press reports.
Per an IB Tomato report, consolidated cosmetics revenue rose from KRW 0.5 billion in 2021 to KRW 10.4 billion in 2025, lifting its share of total revenue from 2.64% to 29.59%. This share is a press tally; segment revenue is not separately shown in the filed results.
In June 2026 the company said it had completed commercialization of a composite bio-composition combining EGF, biotin and oligopeptide-76, applied across the MEDISORB line. Exports go mainly to Europe, the United States and Japan, at roughly USD 3 million to 4 million, according to the CEO.
Domestically, the company supplies core wound-dressing products to large pharmaceutical partners on a B2B basis. The main barrier to overseas expansion is certification, which the CEO said takes three to four years for localized products.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q3 | ₩9.2B | ₩2.4B | 26.0% |
| 2025Q4 | ₩9.4B | ₩2.1B | 22.4% |
| 2026Q1 | ₩9.3B | ₩2.1B | 22.8% |
| 2026Q2 | ₩9.9B | ₩2.8B | 28.0% |
| 2026Q3 | ₩10.8B | ₩2.9B | 27.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩26.7B | ₩5.2B | ₩3.3B | 19.3% | 12.2% | 45.1% |
| 2023 | ₩29.6B | ₩7.1B | ₩5.5B | 24.1% | 17.1% | 31.5% |
| 2024 | ₩30.4B | ₩6.4B | ₩5.7B | 21.0% | 15.3% | 10.7% |
| 2025 | ₩35.2B | ₩7.9B | ₩6.6B | 22.5% | 15.5% | 11.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13
Per the 2025 full-year results, consolidated revenue rose 15.8% year on year, operating profit rose 23.7% and net income rose 16.3%. Growth was driven by higher polyurethane foam dressing sales and the expansion of cosmetics.
Annual revenue went from KRW 26.7 billion in 2022 to KRW 29.6 billion in 2023, KRW 30.4 billion in 2024 and KRW 35.2 billion in 2025, with 2025 the largest year of the four.
Operating profit went from KRW 5.15 billion in 2022 to KRW 7.12 billion in 2023 (up 38.3%), fell to KRW 6.41 billion in 2024 (down 10.1%), and recovered to KRW 7.93 billion in 2025 (up 23.7%). The 2024 dip came in a year when revenue growth slowed to 2.8%.
The operating margin peaked at 24.1% in 2023, dipped to 21.0% in 2024 and reached 22.5% in 2025. Net income attributable to controlling shareholders rose from KRW 3.27 billion in 2022 to KRW 6.62 billion in 2025, increasing for three consecutive years from 2023.
In 2024, total net income (KRW 5.34 billion) was below controlling-shareholder net income (KRW 5.69 billion), reflecting a loss attributable to non-controlling interests.
Operating cash flow was KRW 5.78 billion in 2022, KRW 4.84 billion in 2023, KRW 8.85 billion in 2024 and KRW 8.48 billion in 2025, so cash generation rose in 2024 even as operating profit fell. The debt-to-equity ratio fell from 45.1% in 2022 to 11.7% in 2025.
Quarterly revenue went from KRW 9.22 billion in Q3 2025 to KRW 9.28 billion in Q1 2026 (down 1.0% quarter on quarter), then rose to KRW 9.93 billion in Q2 and KRW 10.8 billion in Q3 2026, up for two consecutive quarters.
Operating profit bottomed at KRW 2.1 billion in Q4 2025 and has risen for three consecutive quarters since. Controlling-shareholder net income peaked at KRW 2.99 billion in Q2 2026 and was KRW 2.37 billion in Q3 2026, up 8.8% year on year.
The subsidiary J&COS has continued to post operating losses and booked impairment charges in 2025. Press coverage of the first half of 2026 cited operating profit of KRW 4.9 billion, up 43.0% year on year.
Wonbiogen operates where wound-care dressings overlap with medical-device cosmetics. FnGuide's company overview says the global wound-dressing market is expected to reach USD 11.2 billion in 2025.
Demand drivers cited include expanded national health insurance coverage, rising private insurance enrollment and population aging. The same source puts the broader cosmetics market at USD 557.9 billion.
Press coverage linked the government's push to revitalize the cosmetics industry to the company's new business lines. Regulation cuts both ways: medical-device approval is demanding, and some cosmetics are classified as medical devices. That raises entry barriers and supports product differentiation.
On intellectual property, the company cites 148 patents and other IP rights as its technology base. Pharmaceutical ODM demand and in-house brand sales coexist, so one channel can cushion the other.
Compared with the drug-pipeline companies in the same sector, Wonbiogen is a medical-materials and device business, so the metrics used to read it differ. As the mix shifts from dressings toward cosmetics, consumer demand and regulatory changes in cosmetics may have a larger effect on results.
The company's 2026 priority is expanding cosmetics domestically and overseas. In January 2026 it said it would set up a retail commerce unit and prepare entry into cosmetics specialty stores.
In November 2025 the company said that once a KRW 2.7 billion production expansion was completed in March 2026, cosmetics output and revenue would rise and profitability would improve. Whether the expansion has been completed and what it contributed will show up in the 2026 annual report.
On the product side, the company plans to extend its composite bio-composition into barrier creams and post-procedure care in the dermo-cosmeceutical range, and into wound dressings. It also plans to build clinical data through domestic medical institutions before pursuing global markets.
The CEO said that if cosmetics reach full scale, USD 20 million in overseas sales within five years is achievable. The company displayed foam dressings and a first-degree burn medical device at the 2026 Korean burn society meeting.
Its marketing centers on sports and regional sponsorships, including a second straight year as an official sponsor of the Gumi ramen festival. The next checkpoints are whether the specialty store entry lifts cosmetics share and whether the expanded capacity converts into cosmetics sales.
The share price sits below the company's book net asset value, with the price-to-book ratio under 1x. At year-end 2025, total equity was KRW 42.6 billion, equity attributable to controlling shareholders was KRW 42.7 billion, and total liabilities were KRW 5 billion, which is small relative to equity.
Market capitalization is below total equity at the same date, so the market values the company below its book assets. On earnings, controlling-shareholder net income for the most recent four quarters totals KRW 8.61 billion, and quarterly figures moved from KRW 2.99 billion in Q2 2026 to KRW 2.37 billion in Q3 2026.
A low valuation relative to net assets reflects equity capacity and reduced debt, but the small earnings base and quarterly swings also make multiples sensitive to results.
Over several years, the operating margin peaked in 2023, dipped in 2024 and recovered in 2025, and that trajectory is the central variable for interpreting value. Dividend payouts should be read alongside the filed results.
Impairments at the subsidiary and the shift toward cosmetics also affect how the earnings base should be interpreted.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13
Total liabilities were KRW 5 billion at year-end 2025 against KRW 42.6 billion of total equity. With the debt burden relative to equity reduced, the company has room to fund cosmetics capacity and overseas certification.
Press-tallied cosmetics revenue reached KRW 10.4 billion in 2025, or 29.59% of total. Q3 2026 revenue of KRW 10.8 billion rose 17.0% year on year. Revenue has risen for two consecutive quarters and operating profit for three, indicating growth that has persisted at the quarterly level.
The EGF-based composite was commercialized across the MEDISORB line, and the company plans to extend it to barrier creams, post-procedure care and wound dressings. Selection for a 2026 innovative bio technology award reflects external recognition of its commercialization potential.
Revenue growth slowed to 2.8% in 2024, and operating profit fell 10.1% to KRW 6.41 billion. The operating margin dropped from 24.1% in 2023 to 21.0% in 2024, and although 2025 recovered to 22.5%, it remains below the 2023 peak.
The subsidiary J&COS continued to post operating losses, and impairment charges were booked in 2025. Press reports say its goodwill fell from KRW 500 million in 2023 to KRW 150 million in 2025.
The company has supported it mainly through intragroup transactions rather than direct capital, leaving the scale of future support uncertain.
Q1 2026 revenue of KRW 9.28 billion fell 1.0% from the prior quarter, and operating profit fell 12.3% quarter on quarter in Q4 2025. Some cosmetics fall under medical-device rules, so certification delays or rule changes could disrupt sales.
J&COS is a loss-making subsidiary that has booked impairments, and its goodwill balance is declining, so further impairment cannot be ruled out. Quarterly checks on how much consolidated profit is affected are needed.
Medical-device cosmetics face long approval processes, and the CEO said localized product certification takes three to four years. Because overseas targets depend on certification timing, regulatory changes or delays could slow growth.
Quarterly operating profit and controlling-shareholder net income swung between Q2 and Q3 2026. With cosmetics at 29.59% of revenue, consumer demand and channel strategy weigh more heavily, so balancing steady dressing demand against cosmetics volatility is the key issue.
Fiscal year 2026 closes. The annual review will show whether goodwill and investment impairment tests for subsidiary J&COS are revisited.
Deadline for the 2026 annual report. Check whether the operating margin holds near 2025's 22.5% and how cosmetics share and subsidiary results are reflected.
Watch whether the new retail commerce unit and specialty store entries show up in results and whether they lift cosmetics share of revenue.
Deadline for the Q1 2027 quarterly report. Check whether revenue holds near the KRW 10.8 billion of Q3 2026 and whether operating profit extends its rise.
Wonbiogen is a company that built cosmetics as a second pillar on top of its wound-dressing ODM base. Filed revenue rose from KRW 26.7 billion in 2022 to KRW 35.2 billion in 2025, and the operating margin, after peaking in 2023 and dipping in 2024, recovered to 22.5% in 2025.
Quarterly data through Q3 2026 show revenue up for two consecutive quarters and operating profit up for three. The debt-to-equity ratio of 11.7% indicates a stable balance sheet.
On the other side, the subsidiary J&COS continues to post operating losses and booked impairments, and that remains a variable for consolidated profit. With cosmetics at 29.59% of revenue on a press-tallied basis, consumer demand and medical-device certification timing now carry more weight.
The next checkpoints are the operating margin in the 2026 annual report, subsidiary results, and the outcome of specialty store entries.
Report written 2026-11-13 · Data as of 2026-11-12
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.